Skip to content

Clinical trials

Neuroblastoma trials in France

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neuroblastoma Country / region: France Clear all

51 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20021
20032
20051
20082
20091
20101
20113
20122
20135
20142
20151
20161
20172
20181
20192
20203
20212
20235
20241
20252
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed27
Unknown status9
Active, not recruiting5
Recruiting5
Terminated3
Not yet recruiting2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Institut Curie5
Novartis Pharmaceuticals5
European Infant Neuroblastoma Study Group - 19994
Gustave Roussy, Cancer Campus, Grand Paris4
Children's Cancer and Leukaemia Group2
Eli Lilly and Company2
European Organisation for Research and Treatment of Cancer - EORTC2
Hoffmann-La Roche2
Societe Internationale d'Oncologie Pediatrique2
St. Anna Kinderkrebsforschung2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neuroblastoma51
Neoplasms14
Rhabdomyosarcoma8
Sarcoma, Ewing8
Brain Neoplasms6
Medulloblastoma6
Glioma5
Osteosarcoma5
Precursor Cell Lymphoblastic Leukemia-Lymphoma5
Recurrence5

Trials

Showing 76 to 51 of 51. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.